about
Bioinformatic and genetic association analysis of microRNA target sites in one-carbon metabolism genesMicroRNAs: novel regulators involved in the pathogenesis of psoriasis?MicroRNA therapeutics: Discovering novel targets and developing specific therapyMicroRNA signatures in liver diseasesMicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functionsThe effect of exposure to a high-fat diet on microRNA expression in the liver of blunt snout bream (Megalobrama amblycephala)Small non-coding RNA signature in multiple sclerosis patients after treatment with interferon-β.High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.Towards computational prediction of microRNA function and activity.Pathophysiology of translational regulation by microRNAs in multiple sclerosis.MicroRNA-203 functions as a tumor suppressor in basal cell carcinomaTwo-tiered approach identifies a network of cancer and liver disease-related genes regulated by miR-122.Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic propertiesMiR-378b Promotes Differentiation of Keratinocytes through NKX3.1.The Role of miR-212 and iNOS in Alcohol-Induced Intestinal Barrier Dysfunction and SteatohepatitisImmunopathologic processes in sympathetic ophthalmia as signified by microRNA profilingMicrovesicles/exosomes as potential novel biomarkers of metabolic diseasesmiR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1Antiviral Stratagems Against HIV-1 Using RNA Interference (RNAi) Technology.miRNAs: from neurogeneration to neurodegeneration.Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.MicroRNAs--micro in size but macro in function.Targeting MicroRNAs in Cancer Gene Therapy.The emerging role of microRNAs in multiple sclerosis.miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs.MicroRNAs as active players in the pathogenesis of multiple sclerosis.miRNA-Based Therapeutic Strategies.Epigenetic dysregulation in systemic lupus erythematosus.Peptide nucleic acids: a review on recent patents and technology transfer.The role of miRNAs in alcohol-induced endotoxemia, dysfunction of mucosal immunity, and gut leakiness.Locked nucleic acid-based in situ hybridisation reveals miR-7a as a hypothalamus-enriched microRNA with a distinct expression pattern.Cellular uptakes, biostabilities and anti-miR-210 activities of chiral arginine-PNAs in leukaemic K562 cells.The effect of miR-7 on behavior and global protein expression in glioma cell lines.VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma.Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century.miR-125b Regulation of Androgen Receptor Signaling Via Modulation of the Receptor Complex Co-Repressor NCOR2.Temporal expression profiles indicate a primary function for microRNA during the peak of DNA replication after rat partial hepatectomy.Nucleoterpenes of thymidine and 2'-deoxyinosine: synthons for a biomimetic lipophilization of oligonucleotides.MicroRNA array analysis of microRNAs related to systemic scleroderma.
P2860
Q21135312-D9EE169B-E702-4586-A2E3-8D7CE200D743Q21144444-065495E1-CF83-4AD2-AC38-2943EB78CBCEQ26747644-D3715E45-64A7-4CE1-8BF1-62033E716CD8Q27488310-7149133E-E142-45A6-810A-F8E7440D02A0Q28297593-42467FFA-9468-4172-8476-F8D999C7ABACQ30391726-413EEF27-EEE9-41E9-8463-EF6350CB50A3Q33765140-2BF86115-7F18-45B5-A25D-0D18CA652E37Q33842759-EB7BB262-5333-4872-8811-24F4B73C87C1Q34080104-FC6D2C90-75DB-4C74-81E2-F1EFDFDEBEFDQ34174676-C6085BDA-8389-4EFF-B226-C1C204C002B7Q34336812-88F675BF-A576-4709-BFE2-6A28F52192ECQ34979073-509C7609-D00F-4B5C-A3F5-EECB8D9AB23FQ34993023-9C639ACD-EDDD-4545-AAB4-F90A637646AEQ35757463-B26B752C-D6E0-4309-A65B-F56057F9EDEBQ36021666-0C28614C-A02B-430E-876C-B5E5777A869DQ36082773-D7E722E8-3C08-4BC0-9A68-45C927C7B452Q36175435-45E04ED9-FA49-48A1-B26F-C40B08EE4872Q36525161-CF34F81A-04B9-4080-975A-FFCF7BFBA7EDQ36870444-9DBBDAB6-08FD-4675-9ABE-447BB54ACA65Q36918118-6F0F8494-0210-4FF9-B046-8CA7D69B3170Q36992190-6B109B41-1A0E-4778-B126-58F457A7498BQ37193000-22E3FEA1-D765-4734-BBDA-7C34DD6989B2Q37255242-7324538F-ECB5-465D-A7DA-2C92CF8286B2Q37628264-5FCA0260-FD4C-4FC5-9E8B-9EA0FA62893BQ37820094-C64790EA-7D32-45EB-9A18-465E80EC498BQ37962609-54382B83-F7DD-4196-8B77-974C6B86AB44Q38064320-3BC09AE5-B11A-4C95-B1B7-B31AD346960DQ38092617-51480B22-2781-4CD1-8BA1-EA433F182EFAQ38152825-3E83D127-1749-444D-8CD4-354E260DC66FQ38176989-3A7ED053-E6A8-4C1B-95D1-A133079588DAQ38254456-38B59F99-8A88-4748-980B-03CA5DE2BD77Q38323747-D04B369B-1158-4898-847B-55800AF9596BQ38324942-692D8523-1D03-4B5E-88A1-891D2D0C5DDFQ39436568-8631D7E2-CF53-4047-9ABC-F5306E71CB40Q42026232-EDAD57D9-B8A7-4B94-814F-42E12C0D917BQ42039163-109635D8-64E3-4973-85A2-C1177E64FF65Q42692995-BCE85AA5-9763-4BB5-A3BE-76049315C8DEQ44118355-8FF39959-159A-497A-BC57-020188C5B401Q46035392-AA41CEAC-CF4F-4FAE-B691-4BD2919C4687Q51553464-A63A5E35-B614-489A-B4E7-BB0D5C8E07A7
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
MicroRNAs as therapeutic targets
@ast
MicroRNAs as therapeutic targets
@en
MicroRNAs as therapeutic targets
@nl
type
label
MicroRNAs as therapeutic targets
@ast
MicroRNAs as therapeutic targets
@en
MicroRNAs as therapeutic targets
@nl
prefLabel
MicroRNAs as therapeutic targets
@ast
MicroRNAs as therapeutic targets
@en
MicroRNAs as therapeutic targets
@nl
P3181
P356
P1476
MicroRNAs as therapeutic targets
@en
P2093
Michael P Czech
P304
P3181
P356
10.1056/NEJMCIBR060065
P407
P577
2006-03-16T00:00:00Z